Needham & Company LLC reaffirmed their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Tuesday morning.

“We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline.”,” Needham & Company LLC’s analyst wrote.

Several other analysts have also recently commented on TBPH. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a buy rating in a research note on Wednesday, August 16th. Evercore ISI initiated coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an outperform rating and a $45.00 target price for the company. Zacks Investment Research upgraded shares of Theravance Biopharma from a sell rating to a hold rating in a research note on Tuesday, September 5th. ValuEngine upgraded shares of Theravance Biopharma from a sell rating to a hold rating in a research note on Wednesday, September 13th. Finally, Robert W. Baird reiterated a sell rating and issued a $22.00 price objective on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $41.86.

Theravance Biopharma (NASDAQ TBPH) traded up $0.06 during mid-day trading on Tuesday, hitting $25.88. 287,800 shares of the stock traded hands, compared to its average volume of 235,993. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44. The company has a quick ratio of 7.21, a current ratio of 7.53 and a debt-to-equity ratio of 1.21.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Parametric Portfolio Associates LLC grew its holdings in shares of Theravance Biopharma by 1.5% during the second quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 217 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 230 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Theravance Biopharma by 8.1% during the second quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 443 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Theravance Biopharma by 3.7% during the second quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after buying an additional 576 shares in the last quarter. Finally, Zacks Investment Management grew its holdings in shares of Theravance Biopharma by 4.6% during the second quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 959 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/theravance-biopharma-tbph-earns-buy-rating-from-needham-company-llc/1752201.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.